Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Long-term bortezomib treatment decreases allergen-specific IgE but fails to amend chronic asthma in mice Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation Year: 2012
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
Free serum IgE suppression with omalizumab and clinical outcomes in asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Relationship between pre-treatment specific IgE and the response to omalizumab therapy Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
The influence of the allergen-specific immunotherapy (ASIT) against the backdrop of an immunomodulator in patients suffering from seasonal allergic rhinitis (SAR) on the level of cytokines, IgE and IgG. Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020
Cytokine production profile of T-lymphocytes and frequence of regulatory T-cells in patients with allergic asthma receiving anti-IgE therapy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002
Correlation between grass pollen specific IgG,IgG4 and IgE in patients treated with SIT Source: Eur Respir J 2002; 20: Suppl. 38, 507s Year: 2002
Specific serum IgE is associated with seasonal symptom load in children with allergic rhinitis Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis Year: 2008
Correlation of changes of IgE with skin reactivity and clinical outcome during specific immunotherapy against home dust in asthmatic subjects Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012
Comparison of sIgG4 levels among allergic patients and patients during ASIT Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001
Serum total IgE level is associated with new-onset asthma and lung function decline in atopics but not in non atopics: A longitudinal study Source: Annual Congress 2010 - Highlights of longitudinal, geographical and time trend studies of asthma and COPD Year: 2010
Chlamydia pneumoniae (Cp)-specific IgE is associated with asthma severitySource: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011